Skip to content

Adam W. Levin

6 papers in the library · 20 citations · publishing 2023-2026

Papers

Differences in attitudes and beliefs about psychedelic-assisted therapy among social workers, psychiatrists, and psychologists in the United States

Journal of Psychedelic Studies August 21, 2023 Stacey B. Armstrong, Adam W. Levin, Yitong Xin et al. 12 citations

Among 856 U.S. mental health professionals—social workers, psychiatrists, and psychologists—there were no differences in confidence that psychedelic-assisted therapy (PAT) would be effective. However, psychiatrists showed a better understanding of PAT than social workers. Psychologists rated PAT as more acceptable than social workers did, and psychologists also rated it as a more reasonable treatment approach than both social workers and psychiatrists. Social workers perceived greater disadvantages of PAT than psychologists and psychiatrists, and they were less likely than both other groups to believe PAT could permanently improve clients' lives. The findings indicate a need for education and training across professions as PAT moves toward approval.

Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder

Journal of Psychedelic Studies September 4, 2025 Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda et al. 4 citations

Over a five-year follow-up period, psilocybin-assisted therapy produced significant and sustained reductions in depression for people with major depressive disorder. Among the 18 participants who completed the study, 67% remained in remission for at least five years after treatment. Anxiety and functional impairment also improved. Qualitative interviews revealed lasting positive changes in mindset, emotional health, and relationships, including enhanced empathy, self-acceptance, and improved interpersonal relationships. No severe adverse events were reported. These findings support the long-term efficacy and safety of psilocybin-assisted therapy for reducing depressive symptoms and improving mental health.

The Epidemiology of Psychedelic Use Among United States Military Veterans

Journal of Psychoactive Drugs September 12, 2024 Katinka Hooyer, Rachel Yehuda, Alan K. Davis et al. 4 citations

About half of U.S. military veterans surveyed reported using psychedelics, most often for healing or treatment (70%) and spiritual purposes (48%). The vast majority (85%) said they benefited from use. Veterans who used psychedelics indicated they would be more likely to use VA services, and they expressed greater interest in psychedelic therapy compared to non-users. However, some adverse outcomes were reported, suggesting that without proper preparation and support, psychedelics may carry risks. The findings point to a potential role for psychedelic-assisted approaches in veteran mental health care.

Personal and social connection to psychedelics is associated with lower drug use stigma among psychiatrists in the United States

Journal of Psychedelic Studies September 17, 2024 Adam W. Levin, Aryan Sarparast, Paul B Nagib et al.

Among a sample of 180 American psychiatrists (mean age 48.4, 65.5% male, 24.1% trainees), about one-third (32.8%) reported personal use of and social connection to psychedelics. Psychiatrists with such personal connection tended to be younger and have fewer years of practice. Those with personal and social connection were more likely to disagree that using illegal drugs is morally wrong, that users should go to prison, are weak-minded, have no future, are poorly educated, are dishonest, or make them angry. Personal and social proximity to psychedelics is associated with less stigma toward drug use and people who use drugs.

Development and assessment of a psychedelic-assisted therapy music playlist for clinical trials: Theory, intentionality, and metrics

Journal of Psychedelic Studies May 28, 2026 Rafaelle L. Lancelotta, Paul B. Nagib, Stacey B. Armstrong et al.

A methodology for designing and evaluating a music playlist for a clinical psilocybin trial was developed, combining theory, therapeutic goals, and metrics. The playlist was structured across pre-peak, peak, and post-peak phases of the psilocybin experience. Spotify API metrics (Beats Per Minute, Danceability, Energy, Valence) and a novel human-rated Transcendence measure were used to assess tracks. Most musical features followed the expected emotional arc of the psilocybin experience, but nature-based tracks were sometimes misclassified as high-energy by the Spotify API, revealing algorithmic limitations. Transcendence ratings indicated continued emotional depth during post-peak phases. This proof-of-concept model shows the value of integrating intentional design with algorithmic and experiential metrics, though Spotify metrics may lack stability and generalizability.